Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.

Baumgarten, Peter

Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. [electronic resource] - Neuro-oncology Feb 2016 - 173-83 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1523-5866

10.1093/neuonc/nov288 doi


Adolescent
Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors--therapeutic use
Astrocytoma--drug therapy
Bevacizumab--therapeutic use
Biomarkers, Tumor--metabolism
Brain Neoplasms--drug therapy
Child
Child, Preschool
Female
Follow-Up Studies
Humans
Immunoenzyme Techniques
Infant
Infant, Newborn
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Neuropilin-1--metabolism
Neuropilin-2--metabolism
Prognosis
Receptors, Vascular Endothelial Growth Factor--metabolism
Survival Rate
Vascular Endothelial Growth Factor A--antagonists & inhibitors
Vascular Endothelial Growth Factor Receptor-1--metabolism
Vascular Endothelial Growth Factor Receptor-2--metabolism
Vascular Endothelial Growth Factor Receptor-3--metabolism
Young Adult